Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

@article{As2014DifferentID,
  title={Different infusion durations for preventing platinum-induced hearing loss in children with cancer.},
  author={Jorrit W van As and H. van den Berg and E. C. van Dalen},
  journal={The Cochrane database of systematic reviews},
  year={2014},
  volume={6},
  pages={
          CD010885
        }
}
  • Jorrit W van As, H. van den Berg, E. C. van Dalen
  • Published 2014
  • Medicine
  • The Cochrane database of systematic reviews
  • BACKGROUND Platinum-based therapy, including cisplatin, carboplatin or oxaliplatin, or a combination of these, is used to treat a variety of paediatric malignancies. Unfortunately, one of the most important adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent this ototoxicity, different platinum infusion durations have been studied. OBJECTIVES To assess the effects of different durations of platinum infusion to prevent hearing loss or tinnitus, or both, in… CONTINUE READING
    1 Citations

    References

    SHOWING 1-10 OF 16 REFERENCES
    Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
    • 361
    • PDF
    Best practice in assessing ototoxicity in children with cancer.
    • 46
    • Highly Influential
    Understanding platinum-induced ototoxicity.
    • 128
    Auditory late effects of chemotherapy.
    • 7